Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Breast Cancer

  Free Subscription


Articles published in JAMA

Retrieve available abstracts of 68 articles:
HTML format



Single Articles


    June 2020
  1. VOELKER R
    Triple-Negative Breast Cancer Drug Receives Approval.
    JAMA. 2020;323:2122.
    PubMed    


    March 2020
  2. RUBIN R
    White Blood Cells Might Provide Clues to Breast Cancer Risk.
    JAMA. 2020;323:1123.
    PubMed    


  3. KURIAN AW, Bernhisel R, Larson K, Caswell-Jin JL, et al
    Prevalence of Pathogenic Variants in Cancer Susceptibility Genes Among Women With Postmenopausal Breast Cancer.
    JAMA. 2020;323:995-997.
    PubMed    


    February 2020
  4. COMSTOCK CE, Gatsonis C, Newstead GM, Snyder BS, et al
    Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening.
    JAMA. 2020;323:746-756.
    PubMed     Abstract available


  5. TOSTESON ANA
    An Abbreviated MRI Protocol for Breast Cancer Screening in Women With Dense Breasts: Promising Results, but Further Evaluation Required Prior to Widespread Implementation.
    JAMA. 2020;323:719-721.
    PubMed    


  6. QUAGLIARELLO V
    Tiny Branches.
    JAMA. 2020;323:711-712.
    PubMed    


  7. COMSTOCK CE, Gatsonis C, Newstead GM, Snyder BS, et al
    Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening.
    JAMA. 2020;323:746-756.
    PubMed     Abstract available


  8. ABBASI J
    Artificial Intelligence Improves Breast Cancer Screening in Study.
    JAMA. 2020;323:499.
    PubMed    


  9. VOELKER R
    Another Targeted Therapy for ERBB2-Positive Breast Cancer.
    JAMA. 2020;323:408.
    PubMed    


    January 2020
  10. KRIST AH, Owens DK, Mangione CM
    Recommendations Related to Genetic Testing for Breast Cancer-Reply.
    JAMA. 2020;323:188-189.
    PubMed    


  11. PINSKY PF
    Recommendations Related to Genetic Testing for Breast Cancer.
    JAMA. 2020;323:187-188.
    PubMed    


  12. DORK T, Park-Simon TW, Hillemanns P
    Recommendations Related to Genetic Testing for Breast Cancer.
    JAMA. 2020;323:188.
    PubMed    


  13. SLAVIN SD
    Doctoring and Deportation.
    JAMA. 2020;323:119-120.
    PubMed    


    December 2019
  14. FAYANJU OLM
    Hiding in Plain Sight.
    JAMA. 2019;322:2173-2174.
    PubMed    


    September 2019
  15. SLOMSKI A
    Adjuvant Therapy for HER2-Positive Breast Cancer.
    JAMA. 2019;322:1134.
    PubMed    


  16. OWENS DK, Davidson KW, Krist AH, Barry MJ, et al
    Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement.
    JAMA. 2019;322:857-867.
    PubMed     Abstract available


  17. NELSON HD, Fu R, Zakher B, Pappas M, et al
    Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA. 2019;322:868-886.
    PubMed     Abstract available


  18. JIN J
    Medications to Reduce Breast Cancer Risk.
    JAMA. 2019;322:900.
    PubMed    


  19. PACE LE, Keating NL
    Medications to Reduce Breast Cancer Risk: Promise and Limitations.
    JAMA. 2019;322:821-823.
    PubMed    


    August 2019
  20. IZZO MC, Bronner G, Shields CL
    Rapidly Progressive Vision Loss in a Patient With Breast Cancer.
    JAMA. 2019 Aug 22. pii: 2749078. doi: 10.1001/jama.2019.12691.
    PubMed    


  21. OWENS DK, Davidson KW, Krist AH, Barry MJ, et al
    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
    JAMA. 2019;322:652-665.
    PubMed     Abstract available


  22. NELSON HD, Pappas M, Cantor A, Haney E, et al
    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA. 2019;322:666-685.
    PubMed     Abstract available


  23. JIN J
    Should I Be Tested for BRCA Mutations?
    JAMA. 2019;322:702.
    PubMed    


    July 2019
  24. SLOMSKI A
    Preventing Cardiotoxicity Associated With Breast Cancer Therapy.
    JAMA. 2019;322:296.
    PubMed    



  25. First PI3K Inhibitor for Breast Cancer.
    JAMA. 2019;322:19.
    PubMed    


  26. CHOI JM
    An Unexpected Asset.
    JAMA. 2019;322:29.
    PubMed    


    June 2019
  27. KEATING NL, Pace LE
    New Federal Requirements to Inform Patients About Breast Density: Will They Help Patients?
    JAMA. 2019;321:2275-2276.
    PubMed    


    May 2019
  28. KERLIKOWSKE K, Miglioretti DL, Vachon CM
    Discussions of Dense Breasts, Breast Cancer Risk, and Screening Choices in 2019.
    JAMA. 2019 May 31. pii: 2735405. doi: 10.1001/jama.2019.6247.
    PubMed    


  29. CRANDALL CJ, Livingston E
    Women's Health: A New JAMA Clinical Insights Series.
    JAMA. 2019;321:1676.
    PubMed    


  30. POLITE BN, Gluck AR, Brawley OW
    Ensuring Equity and Justice in the Care and Outcomes of Patients With Cancer.
    JAMA. 2019;321:1663-1664.
    PubMed    


    April 2019
  31. RUDDY KJ, Ganz PA
    Treatment of Nonmetastatic Breast Cancer.
    JAMA. 2019 Apr 12. pii: 2731086. doi: 10.1001/jama.2019.3927.
    PubMed    


  32. VOELKER R
    Quick Uptakes: Taking the Uncertainty Out of Interpreting BRCA Variants.
    JAMA. 2019;321:1340-1341.
    PubMed    


    February 2019
  33. SLOMSKI A
    BMI Not a Good Proxy for Breast Cancer Risk.
    JAMA. 2019;321:735.
    PubMed    


    January 2019
  34. WAKS AG, Winer EP
    Breast Cancer Treatment: A Review.
    JAMA. 2019;321:288-300.
    PubMed     Abstract available


  35. WAKS AG, Winer EP
    Breast Cancer Treatment.
    JAMA. 2019;321:316.
    PubMed    


  36. DOMCHEK SM
    Risk-Reducing Mastectomy in BRCA1 and BRCA2 Mutation Carriers: A Complex Discussion.
    JAMA. 2019;321:27.
    PubMed    


    December 2018
  37. SLOMSKI A
    Chemoimmunotherapy for Triple-Negative Breast Cancer.
    JAMA. 2018;320:2521.
    PubMed    


  38. HERSHMAN DL, Unger JM, Crew K
    Acupuncture for Aromatase Inhibitor-Related Joint Pain Among Breast Cancer Patients.
    JAMA. 2018;320:2270-2271.
    PubMed    


  39. LIU C, Zhang H, Sun C
    Acupuncture for Aromatase Inhibitor-Related Joint Pain Among Breast Cancer Patients.
    JAMA. 2018;320:2270.
    PubMed    


  40. MAO JJ, Farrar JT
    Acupuncture for Aromatase Inhibitor-Related Joint Pain Among Breast Cancer Patients.
    JAMA. 2018;320:2269-2270.
    PubMed    


    August 2018
  41. LEE GK, Sheckter CC
    Breast Reconstruction Following Breast Cancer Treatment-2018.
    JAMA. 2018 Aug 31. pii: 2701789. doi: 10.1001/jama.2018.12190.
    PubMed    


  42. GROSS AL, Blot WJ, Visvanathan K
    BRCA1 and BRCA2 Testing in Medically Underserved Medicare Beneficiaries With Breast or Ovarian Cancer.
    JAMA. 2018;320:597-598.
    PubMed    


  43. ABBASI J
    Can Acupuncture Keep Women on Their Breast Cancer Drugs?
    JAMA. 2018 Aug 8. pii: 2696922. doi: 10.1001/jama.2018.11068.
    PubMed    


    July 2018
  44. SLOMSKI A
    Many Women With Early Breast Cancer May Not Need Chemotherapy.
    JAMA. 2018;320:332.
    PubMed    


  45. HERSHMAN DL, Unger JM, Greenlee H, Capodice JL, et al
    Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial.
    JAMA. 2018;320:167-176.
    PubMed     Abstract available


  46. ABBASI J
    Immunotherapy Leads to Complete Regression in Late-Stage Breast Cancer.
    JAMA. 2018;320:127.
    PubMed    


    June 2018
  47. GILL J, Obley AJ, Prasad V
    Direct-to-Consumer Genetic Testing: The Implications of the US FDA's First Marketing Authorization for BRCA Mutation Testing.
    JAMA. 2018;319:2377-2378.
    PubMed    


  48. PLEVRITIS SK, Berry DA, Mandelblatt JS
    Contributions of Screening and Treatment to Mortality From Breast Cancer-Reply.
    JAMA. 2018;319:2336.
    PubMed    


  49. CHEN HH
    Contributions of Screening and Treatment to Mortality From Breast Cancer.
    JAMA. 2018;319:2335-2336.
    PubMed    


    May 2018
  50. KEATING NL, Pace LE
    Breast Cancer Screening in 2018: Time for Shared Decision Making.
    JAMA. 2018;319:1814-1815.
    PubMed    


    April 2018
  51. BEJNORDI BE, Litjens G, van der Laak JA
    Machine Learning Compared With Pathologist Assessment-Reply.
    JAMA. 2018;319:1726.
    PubMed    


  52. VAN SMEDEN M, Van Calster B, Groenwold RHH
    Machine Learning Compared With Pathologist Assessment.
    JAMA. 2018;319:1725-1726.
    PubMed    


    March 2018
  53. KATZ SJ, Jagsi R, Morrow M
    Reducing Overtreatment of Cancer With Precision Medicine: Just What the Doctor Ordered.
    JAMA. 2018;319:1091-1092.
    PubMed    


    February 2018
  54. PEACHMAN RR
    Weighing the Risks and Benefits of Hormonal Contraception.
    JAMA. 2018 Feb 28. pii: 2673941. doi: 10.1001/jama.2018.0448.
    PubMed    


  55. HENNEMAN JR
    In Shadow and Light-Images of Transformation Through Breast Cancer.
    JAMA. 2018;319:532-534.
    PubMed    


    January 2018
  56. BALLMAN KV, McCall LM, Giuliano AE
    Axillary vs Sentinel Lymph Node Dissection in Women With Invasive Breast Cancer-Reply.
    JAMA. 2018;319:306-307.
    PubMed    


  57. UNO H, Hassett MJ, Wei LJ
    Axillary vs Sentinel Lymph Node Dissection in Women With Invasive Breast Cancer.
    JAMA. 2018;319:306.
    PubMed    


  58. PLEVRITIS SK, Munoz D, Kurian AW, Stout NK, et al
    Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012.
    JAMA. 2018;319:154-164.
    PubMed     Abstract available


  59. MANSON JE, Aragaki AK, Rossouw JE
    Menopausal Estrogen Therapy and Breast Cancer Mortality-Reply.
    JAMA. 2018;319:193-194.
    PubMed    


  60. HICKEY M, McNamara HC, Mishra GD
    Menopausal Estrogen Therapy and Breast Cancer Mortality.
    JAMA. 2018;319:193.
    PubMed    


    December 2017
  61. EHTESHAMI BEJNORDI B, Veta M, Johannes van Diest P, van Ginneken B, et al
    Diagnostic Assessment of Deep Learning Algorithms for Detection of Lymph Node Metastases in Women With Breast Cancer.
    JAMA. 2017;318:2199-2210.
    PubMed     Abstract available


  62. GOLDEN JA
    Deep Learning Algorithms for Detection of Lymph Node Metastases From Breast Cancer: Helping Artificial Intelligence Be Seen.
    JAMA. 2017;318:2184-2186.
    PubMed    


    November 2017
  63. ENGELHARDT KE, Barnard C, Bilimoria KY
    Wrong-Site Surgery.
    JAMA. 2017;318:2033-2034.
    PubMed    


  64. THOMAS R, Fysh ETH, Smith NA, Lee P, et al
    Effect of an Indwelling Pleural Catheter vs Talc Pleurodesis on Hospitalization Days in Patients With Malignant Pleural Effusion: The AMPLE Randomized Clinical Trial.
    JAMA. 2017;318:1903-1912.
    PubMed     Abstract available


    September 2017
  65. SLOMSKI A
    Low-Fat Diet Reduces Mortality After Breast Cancer.
    JAMA. 2017;318:1099.
    PubMed    


  66. GIULIANO AE, Ballman KV, McCall L, Beitsch PD, et al
    Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
    JAMA. 2017;318:918-926.
    PubMed     Abstract available


  67. LIVINGSTON EH, Li HC
    Breast Cancer Surgery: Less Is More.
    JAMA. 2017;318:909-911.
    PubMed    


  68. MCNEIL M
    Menopausal Hormone Therapy: Understanding Long-term Risks and Benefits.
    JAMA. 2017;318:911-913.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: